NCAM1 and metastatic melanoma: While CTLA4 expression was not significantly different in CD14+, CD15+, and CD56+ cells between the two groups (Figure 3B), the levels were significantly downregulated by approximately 30% in both CD3+ and CD19+ cells from metastatic melanoma patients compared to healthy donors (Figure 3C).